Home > Boards > US Listed > Biotechs >

Avid Bioservices Inc. (CDMO)

Add CDMO Price Alert      Hide Sticky   Hide Intro
Moderator: cjgaddy, stoneroad, biopharm, 4OurRetirement
Search This Board: 
Last Post: 10/21/2019 7:27:19 PM - Followers: 831 - Board type: Free - Posts Today: 0

Avid Bioservices, Inc. (Nasdaq “CDMO”), Tustin CA. http://www.avidbio.com
Four Avid Fact Sheets a/o 8-9-18: https://avidbio.com/publications/brochures/
Avid Bioservices is a CDMO committed to improving the lives of patients by manufacturing products derived from mammalian cell culture for the biotechnology & biopharmaceutical industries. Services include cGMP clinical & commercial product manufacturing, purification, bulk packaging, stability testing & regulatory strategy, submission, and support. The company also provides a variety of process development activities, including cell line development & optimization, cell culture & feed optimization, analytical methods development, and product characterization.

UPCOMING EVENTS: http://ir.avidbio.com/events-and-presentations
Jun3-6/Booth3149: BIO Intl. Convention, Philadelphia - PR: https://tinyurl.com/y4aya583
...1. June5: Ray Marzouk (VP/Quality): “Quality Considerations for Introducing New Products Into Your Facility.”
...2. June5: Gene Yoshioka (Dir/MFG): Roundtable, “Capacity Challenge: How Single-Use is Feeding the Demand for Commercial Biologics Mfg.”
...3. June5: Tracy Kinjerski (VP/BusOP): Interview, “BioProcess Insider Daily” => 6-24-19 Recap article: https://tinyurl.com/y5unnyfo

June27/After Close: FY'19Q4 (fye 4-30-19) Financials & Conf. Call => PR/Transcript: https://tinyurl.com/y6zdjyu2
Aug12-15/Booth322: The Bioprocessing Summit, Boston

Sep5/After Close: Q1/FY20 (q/e 7-31-19) Financials & Conf. Call => Transcript: https://tinyurl.com/y6t8zfur
Sep9-12/Booth903: Biotech Week Boston

Oct9 10amPT: Avid's Annual Shareholders Meeting (14191 Myford Rd, Tustin) 14A/Proxy: https://tinyurl.com/y3dmq9xs
Oct16/Booth__: Outsourced Pharma, San Diego
Dec9-13/Booth__: Antibody Engineering & Therapeutics, San Diego
Mar9-12 2020: BPI US WEST, Santa Clara CA https://lifesciences.knect365.com/bpi-west/
...3-14-20 9:20-9:50am/David Briggs(Sr.Mgr/Mfg-Quality-Sci) & William Leonardi(ProjMgr/BusOP/ClientLiason):
...Technology Workshop/Avid Case Study, “Taking Your Molecule Through Process Validation”

Quotes: Yahoo: Yahoo.com/CDMO Nasdaq: http://www.nasdaq.com/symbol/cdmo RT: http://www.nasdaq.com/symbol/cdmo/real-time
IR: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com, Tim Brons (Media) 415-675-7402 tbrons@vidasp.com

Latest 10K 4-30-19 iss. 6-27-19 http://tinyurl.com/yxukx6t4 PR: http://tinyurl.com/y2k3tftn (Cash 4-30-19=$32.4mm)
Latest 10Q 7-31-19 iss. 9-5-19 https://tinyurl.com/yxvqm45d PR: https://tinyurl.com/y4bxmyvw (Cash 7-31-19=$28.9mm)
ALL SEC filings for CDMO: https://tinyurl.com/yc4zjyzv
CDMO's Corp. Bylaws (a/o 11-14-14): http://tinyurl.com/y8hsppea - Latest 14A/Proxy: https://tinyurl.com/y7qprpg9 (12-7-17)
Poison Pill adopted 3-16-06 for 10yrs: http://tinyurl.com/yvypvh 44-pg SEC filing: http://tinyurl.com/5m57ut BUNGLER explains in plain language: http://tinyurl.com/mft4nd6
...3-17-16 Poison Pill extended until 3-16-2021 https://tinyurl.com/y74glo2n (Form8A Amendment #1)
...Poison Pill TERMINATED eff. 9-23-2019 https://tinyurl.com/y2mzx3xo

Shares O/S as of 8-31-19=56,237,674 - history since 4-2006: https://tinyurl.com/y6t8zfur
...A/O 7-31-19: 3,547,000 stock options outstanding at a wgt.avg. exercise price of $7.56 (pg.12 10Q).
1-12-18: S-3 Shelf Registration filed for up to $125mm https://tinyurl.com/y9qtewpw
...2-20-18: Avid Raises ~$21.8M net, selling 10,294,445@$2.25 (underwriter: Wells Fargo) 8-K: https://tinyurl.com/ya3nenth 424B5: https://tinyurl.com/ycpshgxl
Total INST.+LARGE Holdings: 35,952,779 64.0% a/o 6-30-19 - See https://tinyurl.com/y6e6narf


1. Tappan Street (Prasad Phatak): 4,854,100 8.7% (+337,993 a/o 12-31-18 13G: http://tinyurl.com/yxrpla3b )
2. IsZo Capital Mgt. (Brian Sheehy): 4,778,123 8.5% (+1,532,748 a/o 6-30-19 Nasdaq Inst.)
3. Eastern Capital (Kenneth Dart): 4,300,992 7.6% (a/o 12-7-17 14A: https://tinyurl.com/y7qprpg9 acq. 10-2015)
4. Blackrock Inc. (Larry Fink): 3,790,286 6.8% (+266,015 q/e 6-30 Nasdaq Inst.)
5. Ronin Trading (John Stafford III+Roger Farley): 2,638,450 4.7% (a/o 4-17-18 13D: https://tinyurl.com/ycf7d2uk )
6. Vanguard Group 2,676,002 4.8% (+19,667 q/e 6-30-19 Nasdaq Inst.)
7. Snyder Capital 2,242,292 4.0% (-111,525 a/o 6-30-19 Nasdaq Inst.)
8. Altravue Capital 2,108,812 3.8% (+133,337 a/o 6-30-19 Nasdaq Inst.)
9. State Street 939,873 1.7% (+75,776 a/o 6-30-19 Nasdaq Inst.)
Inst. Holdings (Nasdaq) - updated 45-days after each qtr-end: http://www.nasdaq.com/symbol/cdmo/institutional-holdings
INSIDER-Trans: https://tinyurl.com/ycpw4j9z  (formerly PPHM thru 2017: http://tinyurl.com/ypkow8 )
Short Interest, updated twice a month: https://www.nasdaq.com/symbol/cdmo/short-interest
A-T-M (At-The-Market) Sales 3/2009 - 7/14/17 ($272,500,000gr./34,869,747sh=$7.81/sh): http://tinyurl.com/yagmu2on
PPHM shares were 1:7 Reverse Split eff. 7-10-17 (315mm/$.606=>45mm/$4.24) http://tinyurl.com/yymtzcm9
PPHM shares were 1:5 Reverse Split eff. 10-19-09 (~237mm/$.64=>~47.4mm/$3.20) http://tinyurl.com/ykuw588
Potential Value: 9-19-2017: Catalent acquires CDMO Cook Pharmica for $950M ($179Msales x 5.3; EV/EBITDA=17.3) http://tinyurl.com/yd46m8py

AVID TEAM: https://avidbio.com/team - Open Jobs: https://avidbio.applicantpro.com/jobs
7-26-19: Catherine Mackey, PhD (ex Pfizer VP) joins Avid's BOD https://tinyurl.com/y3xhqmvm
5-8-19: Richard (Rick) B. Hancock named Interim President/CEO; Roger Lias resigns https://tinyurl.com/y4pqdwyc
7-16-18: Daniel Hart (ex-ENO Holdings) joins Avid as CFO https://tinyurl.com/ychz45p2
7-16-18: Michael Faughnan (ex-Lonza/WuXi Biologics) joins Avid as Sr.Dir./BusDev/WestC https://tinyurl.com/yaozdggz (Left 5-2019)
5-29-18: Sandra C. Carbonneau (ex-Lonza) joins Avid as Dir./BusDev./EastCoast https://tinyurl.com/ybvrwn2l
5-8-18: Magnus Schroeder (ex-AGC Biologics) joins Avid as VP/Process Sciences https://tinyurl.com/y7tpswaw
2-23-18: CFO Paul Lytle voluntarily resigns eff. 5-24-18 (2-23-18 +90days), "CFO search underway" https://tinyurl.com/ybnjzbv6
9-11-17: Roger J. Lias (ex-Allergan) to become Avid’s CEO and join PPHM’s BOD eff. 9-25-17 https://tinyurl.com/yddufw4s (left 5-8-19)
11-29-17: Tracy L. Kinjerski (ex-CMC Biologics) joins Avid as VP/Bus.Operations https://tinyurl.com/yc4zenkc
Profiles of all 6 BOD members & Compensation as of 5-8-19: https://tinyurl.com/y9lkl4q2 (Lias left 5-8-19)
...Joseph Carleone/Chair, Richard Hancock, Gregory Sargen, Joel McComb, Mark Bamforth, Patrick Walsh

CDMO/Form4’s for 7-person BOD (Options Awarded):
...Joseph Carleone/Chairman, Richard Hancock, Gregory Sargen, Joel McComb: 75,000 @4.67, vesting monthly over 3yrs beg. 12-27-17
...Patrick Walsh: 75,000 @4.08, vesting monthly over 3yrs beg. 11-20-17
...Mark Bamforth: 75,000 @3.88, vesting monthly over 3yrs beg. 11-17-17
...Roger Lias: 150,000 @3.19, vesting in 4 annual installments beg. 9-25-18 <=Resigned 5/8/19
...Richard Hancock(Interim CEO): 46,540 @4.53, vesting annually over 4yrs beg. 5-7-19
...Catherine Mackey(BOD): 31,200 @6.38, vesting monthly over 3yrs beg. 8-25-19
...Mark Bamforth pur. 50,000@$4.50 on 10-27-17 (open mkt) http://tinyurl.com/ya7pyyu5
...Mark Bamforth pur. 50,000@$2.25 on 2-15-18 (dir. public offering)  https://tinyurl.com/ybsn2gy6
...Joel McComb pur. 50,000@$2.25 on 2-15-18 (dir. public offering) https://tinyurl.com/ybx5saje SOLD 50,000@6.53 on Sept19-20 2018: https://tinyurl.com/y78acunh
...Joseph Carleone pur. 44,445@$2.25 on 2-15-18 (dir. public offering) https://tinyurl.com/ybskshrk
...Joseph Carleone pur. 10,000@$5.05 on 9-10-19 (open mkt.) https://tinyurl.com/y4mfdmqv (after=54,445)
...Richard Hancock pur. 10,000@$5.09 on 9-10-19 (open mkt.) https://tinyurl.com/y2omcovz (after=10,000)
10-24-17: Peregrine Adds Patrick D. Walsh to BOD, "An Industry Veteran with 30+yrs Experience Leading Successful CDMO Org’s” http://tinyurl.com/y3jo2rv7
10-19-17: Peregrine Adds Mark R. Bamforth to BOD, "10yrs/Genzyme; 30yrs of biologics leadership experience, incl. founding 2 CDMOs" http://tinyurl.com/y6ydcaof

ANALYST COVERAGE: http://ir.avidbio.com/analyst-coverage
Janney Capital - Paul Knight (init. 6-25-18): Buy/PT=$10 https://www.janney.com Coverage: https://jms.bluematrix.com/docs/html/BLUE.html
H.C. Wainwright - Joseph Pantginis (init. 3-24-18) Buy/PT=$11 https://tinyurl.com/ya8hew4c Coverage: https://hcwco.com/services/research
First Analysis Securities - Steven Schwartz & Tracy Marshbanks (init. 3-13-18 https://tinyurl.com/yabgz2ff ): OverWgt/PT=$8
"In transition": Wells Fargo (init. 3-15-18 https://tinyurl.com/yae5bjn5 ): Outperform/PT=$3.50
"In transition": Noble Life Science Partners - Caroline Palomeque https://noblecapitalmarkets.com/life-science (init. 7-16-15); 12-12-17: Buy/PT=$10

9-5-19: CDMO's Revs & Burns By Qtr Table, FY07/Q1 thru FY19/Q4 (q/e 7-31-19): https://tinyurl.com/y6t8zfur5
......Avid FY20 (fye 4-30-20) revenues guidance: $64-67M; committed backlog=$61mm at 7-31-2019.
7-8-19: Avid Signs New Top10 Global Pharma and Expands Existing Cust. Relationship https://tinyurl.com/yyq8zgb9
6-27-19: "The 5 new clients signed in late FY2018 contributed significantly to revenue diversification in FY2019." SEE CUST SPLITS for FY19: http://tinyurl.com/y5j4dlsv
4-24-18: ”In recent weeks, Avid has signed new agreements with 3 addl. undisclosed intl. drug dev. companies (that’s 4 thus far in CY2018)” https://tinyurl.com/y89whc8d
3-1-18: Acumen Pharm. selects Avid for Process Dev. & Mfg. of ACU193 (Alzheimer’s) https://tinyurl.com/y8jvwleq http://www.acumenpharm.com
2-21-18: Enzyvant selects Avid to commercially mfg. RVT-801 (Farber disease) https://tinyurl.com/yd5xhcx8 http://www.enzyvant.com
2-12-18: Peregrine’s Legacy PS-Targeting IP Sold to ONCOLOGIE INC. (Boston, CEO: Laura E. Benjamin) for $8M/upfront, $95M/milestones https://tinyurl.com/yam8gb3h
...NOTE: 2-13-18: Oncologie Licenses Mologen’s immunotherapeutic ‘lefitolimod’ (TLR9 agonist) https://tinyurl.com/y9z54f4x “ONCOLOGIE is backed by top-tier intl. investors and has the objective to dev. novel personalized medicines in the field of immuno-oncology."
2-28-17: Avid & Cook (acq. by Catalent 12-2017 for $950M; $179Msales x 5.3; EV/EBITDA=17.3) remain Halozyme's 2 CMO's (“working to scale-up/validate/qualify Avid II/Myford for Roche collab.”): http://tinyurl.com/h75teta

FACILITIES: https://avidbio.com/services/#state-art-facilities
10-8-19: Avid Announces Completion of Expansion of Process Dev. Capabilities & Labs https://tinyurl.com/y3hfwst9
...will “significantly accelerate Avid’s ability to drive efficient & rapid on-boarding of new cust. pgms progressing to mfg.”
4-24-18: Avid adding Process Dev. Labs, upgrading capabilities (in phases; total will be >6000sq; 1st one ready Q3CY18/Jul-Sep'18) https://tinyurl.com/y89whc8d
5-2017: Avid II (Myford) adds 2 MilliporeSigma Mobius 2,000L single-use bioreactors; total mfg. capacity now ">11,000L". http://tinyurl.com/ky7bmu4
5-10-17: Halozyme comments on Avid II(Myford) expansion in their 3-31-17/10Q pub. 5-9-17: http://tinyurl.com/mrl34uk
..."validation of the new facility is scheduled to end in Q2/2017… Once this new facility is approved, it will become the primary source for Roche of bulk rHuPH20.”
6-2-16: Corp.Update – Avid Expansion & Drug Development - http://tinyurl.com/zvmhqmr
3-7-16/Avid II: Formal Commissioning of Avid's New 40,000sq "Myford" Facility, “single-use/fully disposable” (potentially $40M addl revs) http://tinyurl.com/y5jmfpo3
12-10-15/Avid II: Avid Expansion into MYFORD Facility now GMP-run ready (potential +$40mm sales) - contemplating further expansion http://tinyurl.com/y539yut4
12-10-14: Avid to Double Mfg. Capacity(“Myford Expansion”) http://tinyurl.com/y2sqoy2u & http://tinyurl.com/kmdgq8t

PRESENTATIONS & ARTICLES: http://ir.avidbio.com/events.cfm
10-25-18/BioPharma: Roger Lias Interview, “Avid expansion to Triple Process Dev. Capacity” https://tinyurl.com/ybtuk29m
Sept2018/BioTechWEEK: Tracy Kinjerski (VP/BusOP) interview: Avid’s differentiators (6mins.) https://www.youtube.com/watch?v=x3tzo4pZivk
1-29-18: NobleCon14 - 14th Annual Inv. Conf., Ft.Laud. => Roger Lias' webcast/slideshow https://tinyurl.com/yanwk9yo
11-15-17/Outsourcing-Pharma: “How This R&D Company (Peregrine) is Transitioning to a Pure-Play CDMO: ‘Opportunities Are Almost Endless’" - Recap of interviews with Steve King & Avid Pres. Roger Lias http://tinyurl.com/y7dv9faz

9-5-19: Qtly. Conf. Call (Hancock/Hart/Kinjerski) PR & Transcript https://tinyurl.com/y6t8zfur
6-27-19: Qtly. Conf. Call (Hancock/Hart/Kinjerski) PR & Transcript https://tinyurl.com/y6zdjyu2
...Rick Hancock, "Most importantly, during Q4, the Company achieved positive income, generating cash from dev. & mfg. operations for the 1st time since the beginning of the CDMO transition (Jan'18)."
3-11-19: Qtly. Conf. Call (Lias/Hart) PR & Transcript http://tinyurl.com/yy6dvjvc
12-3-18: Qtly. Conf. Call (Lias/Hart//Kinjerski) PR & Transcript https://tinyurl.com/y9n374kp
10-4-18: ASM/2018 (@Myford Facility) - Roger Lias’ Slideshow & Attendee Report https://tinyurl.com/yctfzhlb
9-10-18: Qtly. Conf. Call (Lias/Hart) PR & Transcript https://tinyurl.com/y8oc6hx8
...Roger Lias, "During the qtr, we advanced the projects of our existing active clients and continue to engage with numerous potential new customers."
7-16-18: Qtly. Conf. Call (Lias/Kinjerski) PR & Transcript https://tinyurl.com/yaozdggz
...Roger Lias, “In a short period, we’ve established a targeted business dev. operation that is actively providing visibility for Avid Bioservices within our fast growing but competitive marketplace.”
3-12-18: Qtly. Conf. Call (Lias/Kinjerski/Lytle) PR & Transcript https://tinyurl.com/yakdl4wj
...Roger Lias, ”I'm pleased to be able to report that in a very short period of time we've generated significant interest from both emerging & growth biopharmaceutical players and from pharmaceutical multinationals. I'm confident that the plan we're executing will drive a considerable increase in backlog and the opportunity to further enhance capacity utilization in the future.”
......From the 3-12-18 PR: “At present, we are in late-stage negotiations with several potential new customers and expect to announce the executed agreements before the end of the FY[4-30-18].”
1-18-18: ASM/2017 (@Myford Facility) - Roger Lias’ Slideshow & Attendee Reports https://tinyurl.com/yca6enbr 12-7-17 PROXY/14A: https://tinyurl.com/y7qprpg9
12-11-17: Qtly. Conf. Call (Lias/Lytle) Transcript https://tinyurl.com/ybycb2s6
...Roger Lias, "the company is undergoing a broad-scale transformation, the goals of which are to shift complete focus to the Avid Bioservices CDMO business and the complete divestiture of all of Peregrine's legacy R&D assets, which include bavituximab."
9-11-17: Qtly. Conf. Call (King/Lias/Lytle) Transcript http://tinyurl.com/y9y8qdac
...Steve King: “For this reason, we have concluded that in order to best position Peregrine’s R&D assets for successful development, they should be advanced by a partner with the appropriate expertise and ample resources to invest in the necessary clinical trials. To that end, we have been working diligently towards the transformation of the overall business to becoming a pure-play CDMO, while assessing the best strategic options for the R&D assets that would allow stockholders to directly see the future value from their continued developments. By partnering & eliminating future R&D expenditures, we believe we are best positioning Avid for future growth. Through reinvestment & expansion, we believe we will attract new customers and extend current contracts that will help position Avid as a leading U.S. CDMO. We are moving forward expeditiously with strategic discussions as we recognize the need to move quickly both from the R&D & CDMO standpoints. We hope to bring this process to completion over the coming months and will update you on our progress.”
7-14-17: Qtly. Conf. Call (King/Shan/Lytle) Transcript http://tinyurl.com/yb4wulvu
...Steve King: “We are seriously considering the possibility of separating our 2 distinct businesses, Avid and R&D/PS-Targeting.”
3-13-17: Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript http://tinyurl.com/grhwjvy
...Steve King: “We believe the recent improvement of stock price is a growing recognition of the value of Avid, and having the full value of the Avid business reflected in our stock price is a top priority.”
12-12-16: Qtly. Conf. Call (King/Shan/Hutchins/Lytle) Transcript http://tinyurl.com/hhn4gga
...Steve King: “Our goal is to bring the overall company to profitability within the next 18mos. We believe just the value of Avid Bioservices is far greater than our current market cap and is only growing in value."
10-13-16 ASM/2016: ATTENDEE Reports & Link to CEO Steve King's 35min/45slide webcast: http://tinyurl.com/jx7ouay

Feb. 2018: Peregrine Pharmaceuticals completed its Mid’17-Early’18 Transition to a Pure-Play CDMO
(Contract Development & Manufacturing Organization), Avid Bioservices, Inc. - CEO: Roger Lias.

**FULL PPHM=>CDMO Transition History (Ronin/SWIM): https://tinyurl.com/ybqvzwhg
1-8-17: Peregrine chgs. name to “Avid Bioservices, Inc.”; new ticker: “CDMO” (+CDMOP) https://tinyurl.com/y8vhjow4
2-12-18: Peregrine’s Legacy PS-Targeting IP Sold to ONCOLOGIE INC. (Boston, CEO: Laura E. Benjamin) for $8M/upfront, $95M/milestones https://tinyurl.com/yam8gb3h
...12-13-18/8-K: Overview of Oncologie sale: https://tinyurl.com/yab9c6cr
NOTE: “PS-targeting Exosome tech. not included; back to UTSW", see: https://tinyurl.com/yakdl4wj

Click here for an ARCHIVE of the History of Peregrine’s Anti-PS/Bavituximab Platform - MOA, Trials, and Activity over the years, from early 2000’s thru 2017, prior to being Sold to ONCOLOGIE:
Of Interest (post Oncologie Sale):
4-20-18/AACR’18: MSKCC(LudwigCC) Tweets about 2 WolchokLAB/”PPHM” Anti-PS Posters https://tinyurl.com/ycgjhvqa
4-26-18: New Bavi+Keytruda/LIVER Ph2 IST Trial, Sponsor=UTSW, Collab=MERCK https://tinyurl.com/y7fd9vdb
6-7-18: Oncologie Obtains $16.5M Seed Funding Led by Pivotal bioVenture Partners China Fund https://tinyurl.com/ybrrbgg7
6-7-18/BioCentury: Laura Benjamin states, “Oncologie plans to begin a trial mid-summer '18 evaluating Bavi to treat HCC and a P-O-C trial in Gastric cancer in 1Q19/2Q19.” https://tinyurl.com/ycb8r7sm
12-3-18: During q/e 10-31-18, Avid sold remaining legacy R&D asset, r84(anti-VEGF), to Oncologie for $1.0M upfront. Avid is eligible to receive up to an addl. $21M in dev/reg./comm. milestones, and low to mid-single digit royalties on net sales upon commercialization of products utilizing r84 https://tinyurl.com/y9n374kp

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CDMO News: Avid Bioservices Names Richard Richieri as Chief Operations Officer 10/09/2019 12:30:00 PM
CDMO News: Avid Bioservices Announces Completion of Expansion of Process Development Capabilities and Laboratory Infrastructure 10/08/2019 08:05:00 AM
CDMO News: Avid Bioservices Announces Termination of Stockholder Rights Plan 09/23/2019 04:05:00 PM
CDMO News: Avid Bioservices Reports Financial Results for First Quarter Fiscal 2020 and Recent Developments 09/05/2019 04:05:00 PM
CDMO News: Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 09/04/2019 04:05:00 PM
#331621  Sticky Note Now Avid Bioservices CDMO captures attention of-IIS biopharm 09/08/19 06:58:43 PM
#331619  Sticky Note PEREGRINE’s AntiPS/IP and 2017 Transition to Pure CDMO cjgaddy 09/08/19 09:19:06 AM
#331618  Sticky Note 9-5-19 Qtly CC-Transcript, PR(Q1FY20/qe7-31-19), Avid Revs History Table cjgaddy 09/08/19 08:00:15 AM
#329801  Sticky Note 3-11-19 Qtly CC-Transcript, PR(Q3FY19/qe1-31-19), Avid Revs History Table cjgaddy 03/12/19 12:35:21 PM
#332131   Another late after hour trade??? 51,278 horselover45 10/21/19 07:27:19 PM
#332130   Analyst coverage has been updated. cheynew 10/21/19 05:31:54 PM
#332128   interesting. horselover45 10/21/19 12:45:42 PM
#332127   Why is Ampersand hiding info to maximize shareholder biopharm 10/21/19 11:30:09 AM
#332126   Bollinger bands are tight. Hopefully it breaks cheynew 10/21/19 10:35:57 AM
#332125   Maybe a year or so? At least cheynew 10/21/19 10:26:47 AM
#332124   Do you remember as to how long the horselover45 10/21/19 10:20:28 AM
#332123   Seems like mgt should update their analyst coverage cheynew 10/21/19 10:11:10 AM
#332122   Roche: The ultimate insider view biopharm 10/20/19 11:33:49 AM
#332121   Eb, thanks for the updates ...greatly appreciated. biopharm 10/19/19 09:13:06 PM
#332120   Today's action feels different. The upward trend is biopharm 10/19/19 07:02:07 PM
#332119   What was your take away from Friday? Namtro 10/19/19 12:59:55 PM
#332118   There are many Subcutaneous BLAs pending ...Avid CDMO biopharm 10/19/19 08:33:50 AM
#332117   progress... slow but progress.. jakedogman1 10/18/19 05:57:04 PM
#332116   One of our largest shareholders as described by r622102675 10/18/19 01:12:22 PM
#332115   The last time I made mention of that ElSid18 10/18/19 09:48:13 AM
#332114   today is option exp day so anything can jakedogman1 10/18/19 08:49:03 AM
#332113   If we CLOSE above $5,50 today, on good ElSid18 10/18/19 08:12:17 AM
#332112   Is it for real, or something else? Namtro 10/17/19 07:01:34 PM
#332111   Today's action feels different. The upward trend is ElSid18 10/17/19 01:45:54 PM
#332110   Roche provides pipeline update Oct 16 2019 jakedogman1 10/17/19 10:06:12 AM
#332109   So milestone payments are years away. Now corporalagarn 10/17/19 10:01:34 AM
#332108   From an expert that is knowledgeable on these bfiest 10/17/19 09:00:48 AM
#332107   Eb... thanx for the info/questions asked... spot on... r622102675 10/17/19 07:25:36 AM
#332106   Thanks eb0783, for sharing your insights/memories from drontle2 10/17/19 07:21:58 AM
#332105   Thanks For Your Informative Post To StockHOLDERS,eom. 4OurRetirement 10/16/19 10:39:29 PM
#332104   Here is the second/last post of my notes eb0783 10/16/19 10:26:26 PM
#332103   Again, they said milestones are "down the road." eb0783 10/16/19 10:15:54 PM
#332102   my experience w/ mgmt is double check.. the jakedogman1 10/16/19 10:03:20 PM
#332101   The implication was a milestone may be expected eb0783 10/16/19 09:35:02 PM
#332100   Looks like there is no payout for IST bigbro1 10/16/19 07:03:42 PM
#332099   Thank you. bfiest 10/16/19 06:49:06 PM
#332098   w respect to ongoing trials, oncologie along with jakedogman1 10/16/19 06:31:12 PM
#332097   OK, Here is the first of 2 (probably) eb0783 10/16/19 06:04:14 PM
#332096   Whats up with all new analyst coverage ? bigbro1 10/16/19 05:51:45 PM
#332095   Avid Bioservices initiated with an Overweight at Stephens bigbro1 10/16/19 05:49:26 PM
#332094   AfterHours BID UP, $5.09 Despite $5.01 Closing Price... 4OurRetirement 10/16/19 04:43:59 PM
#332093   Extracellular vesicles as a novel source of biomarkers biopharm 10/16/19 10:35:01 AM
#332092   The more "massive" the climbs/falls, the easier it ElSid18 10/16/19 09:19:47 AM
#332091   EISid, With the massive climbs/falls in the share price drontle2 10/16/19 09:11:24 AM
#332090   Go to Stockcharts.com and use the drop-down menu ElSid18 10/16/19 08:33:14 AM
#332089   Very interesting and I wonder if some realize biopharm 10/16/19 08:30:54 AM
#332088   analyst had good ratings in health care... jakedogman1 10/16/19 08:30:37 AM
#332087   Bid now 5.19 for only 200 shares. cheynew 10/16/19 08:27:05 AM
#332086   Here is the analyst: cheynew 10/16/19 08:22:59 AM
#332085   Avid Bioservices initiated with a Buy at Craig-Hallum bigbro1 10/16/19 08:17:09 AM
#332084   I would like to clarify my reply... I only Namtro 10/16/19 08:02:13 AM
#332083   As always, thank YOU, very much appreciated!!! Was Namtro 10/15/19 10:37:59 PM
#332082   We came down to $5.06 for the THIRD ElSid18 10/15/19 10:22:58 PM
#332081   ElSid, are we going lower yet, or was Namtro 10/15/19 05:45:31 PM